Invesco Dynamic Pharmaceuticals ETF

Fund Description
The Invesco Dynamic Pharmaceuticals ETF (Fund) is based on the Dynamic Pharmaceutical IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including: price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US pharmaceuticals companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

As of Sept. 30, 2019

Growth of $10,000

Data beginning 10 years prior to the ending date of Sept. 30, 2019. Fund performance shown at NAV.

Fund Data
Dynamic Pharmaceuticals ETF PJP
Intraday NAV (IIV) PJPIV
Number of Securities 30
CUSIP 46137V662
Listing Exchange NYSE Arca
30-Day SEC Yield 0.94%
30-Day SEC Unsubsidized Yield 0.94%
Total Expense Ratio 0.56%

Underlying Index Data
Dynamic Pharmaceuticals Intellidex DZRTR
Index Provider ICE Data Indices, LLC

Fund Inception: June 23, 2005
Shares are not FDIC insured, may lose value and have no bank guarantee.

Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 50,000 Shares.

Index returns do not represent Fund returns. An investor cannot invest directly in an index.

Neither the underlying Index nor the benchmark indexes charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown; nor do any of the indexes lend securities, and no revenues from securities lending were added to the performance shown. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in the Fund.

The S&P Composite 1500 Pharmaceuticals Index consists of all pharmaceuticals stocks included in the S&P Composite 1500 Index.
Top Fund Holdings (%)

<table>
<thead>
<tr>
<th>Name</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>5.67</td>
</tr>
<tr>
<td>Pfizer</td>
<td>5.04</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>5.00</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>4.94</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>4.93</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>4.89</td>
</tr>
<tr>
<td>Merck</td>
<td>4.84</td>
</tr>
<tr>
<td>Amgen</td>
<td>4.63</td>
</tr>
<tr>
<td>Perrigo</td>
<td>3.22</td>
</tr>
<tr>
<td>Medicines</td>
<td>3.14</td>
</tr>
<tr>
<td>Medicines</td>
<td>3.14</td>
</tr>
</tbody>
</table>

Health Care Equipment 4.89
Pharmaceuticals 56.04

Fund Subindustry Allocations (%)

| Pharmaceuticals | 56.04 |
| Biotechnology   | 39.07 |
| Health Care Equipment | 4.89 |

Fund Market-Cap Allocations (%)

| Weighted Market Cap (SMM) | 75,433 |

Return on Equity 25.47%
P/E Ratio 12.39
P/B Ratio 3.09

About risk

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund’s return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.

The Fund is non-diversified and may experience greater volatility than a more diversified investment. Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

Investments focused in a particular industry, such as pharmaceuticals, are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

The Intraday NAV is a symbol representing estimated fair value based on the most recent intraday price of underlying assets. Volatility is the annualized standard deviation of index returns. Sharpe Ratio is a risk-adjusted measure calculated using standard deviation and excess return to determine reward per unit of risk. A higher Sharpe Ratio indicates better risk-adjusted performance. Correlation indicates the degree to which two investments have historically moved in the same direction and magnitude. Alpha is a measure of performance on a risk-adjusted basis. Weighted Harmonic Average Stock Price-to-Earnings Ratio (P/E Ratio) is the share price divided by earnings per share. It is measured on a 12-month trailing basis. Weighted Harmonic Average Stock Price-to-Book-Value Ratio (P/B Ratio) is the ratio of a stock’s market price to a company's net asset value. Weighted Harmonic Average is a method of calculating an average value that lessens the impact of large outliers and increases the impact of small ones. Weighted Average Return on Equity is net income divided by net worth. Weighted Market Capitalization is the sum of each underlying securities’ market value. The 30-Day SEC Yield is based on a 30-day period and is computed by dividing the net investment income per share earned during the period by the maximum offering price per share on the last day of the period. The 30-Day SEC Unsubsidized Yield reflects the 30-day yield if the investment adviser were not waiving all or part of its fee or reimbursing the fund for part of its expenses. Total return would have also been lower in the absence of these temporary reimbursements or waivers. Beta is a measure of risk representing how a security is expected to respond to general market movements. Smart Beta represents an alternative and selection index based methodology that seeks to outperform a benchmark or reduce portfolio risk, or both. Smart beta funds may underperform cap-weighted benchmarks and increase portfolio risk.

Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.

The Global Industry Classification Standard was developed by and is the exclusive property and a service mark of MSCI, Inc. and Standard & Poor's.

ICE Data Indices, LLC, is used with permission. Dynamic Pharmaceutical Intellidex Index (“Index”) is a service/trade mark of ICE Data Indices, LLC or its affiliates and has been licensed for use by Invesco Capital Management LLC, in connection with the Invesco Dynamic Pharmaceuticals ETF (the “Product”). Neither Invesco Capital Management LLC, Invesco Exchange-Traded Fund Trust nor the Product, as applicable, is sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, its affiliates or its Third Party Suppliers (“ICE Data and its Suppliers”). ICE Data and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally, in the Product particularly, the Trust or the ability of the Index to track general market performance. Past performance of an Index is not an indicator of or a guarantee of future results.

ICE DATA AND ITS SUPPLIERS DISCLAIM ANY AND ALL WARRANTIES AND REPRESENTATIONS, EXPRESS AND/OR IMPLIED, INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, INCLUDING THE INDICES, INDEX DATA AND ANY INFORMATION INCLUDED IN, RELATED TO, OR DERIVED THEREFROM (“INDEX DATA”). ICE DATA AND ITS SUPPLIERS SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY WITH RESPECT TO THE ADEQUACY, ACCURACY, TIMELINESS OR COMPLETENESS OF THE INDICES AND THE INDEX DATA, WHICH ARE PROVIDED ON AN “AS IS” BASIS AND YOUR USE IS AT YOUR OWN RISK.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund, investors should ask their advisor(s) for a prospectus or download one at invesco.com

Note: Not all products available through all firms or in all jurisdictions.